Covaxin Phase 1 Trial Clears Lancet Review, Phase 3 Trial Ongoing

Covaxin, India's first indigenous vaccine against COVID-19, showed enhanced immune response without any serious side effects in the Phase 1 trials, according to the results published in well-respected Lancet Infectious Disease journal on Friday.

Similar peer-reviewed studies for the Phase 2 are still awaited and Phase 3 trials are ongoing even as the government continues to give out the jabs to lakhs of front-line workers. While the first two phases of vaccine trials usually focus on their safety, the third stage generally determines its efficacy.

Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), Pune, Covaxin has been granted emergency use authorisation in clinical trial mode by the Indian government.